AP475A - Pharmaceutical formulations containing hyaluronic acid. - Google Patents
Pharmaceutical formulations containing hyaluronic acid. Download PDFInfo
- Publication number
- AP475A AP475A APAP/P/1993/000491A AP9300491A AP475A AP 475 A AP475 A AP 475A AP 9300491 A AP9300491 A AP 9300491A AP 475 A AP475 A AP 475A
- Authority
- AP
- ARIPO
- Prior art keywords
- dosage amount
- weight
- component
- skin
- dosage
- Prior art date
Links
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 289
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 287
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 286
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 74
- 210000003491 skin Anatomy 0.000 claims abstract description 290
- 210000001519 tissue Anatomy 0.000 claims abstract description 225
- 239000003814 drug Substances 0.000 claims abstract description 151
- 229940079593 drug Drugs 0.000 claims abstract description 113
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 96
- 201000010099 disease Diseases 0.000 claims abstract description 95
- 210000002615 epidermis Anatomy 0.000 claims abstract description 88
- 230000000699 topical effect Effects 0.000 claims abstract description 83
- 150000003839 salts Chemical class 0.000 claims abstract description 75
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 69
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 69
- 239000012634 fragment Substances 0.000 claims abstract description 50
- 150000002148 esters Chemical class 0.000 claims abstract description 40
- 230000002035 prolonged effect Effects 0.000 claims abstract description 27
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 18
- 230000009885 systemic effect Effects 0.000 claims abstract description 11
- 229940124531 pharmaceutical excipient Drugs 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims description 292
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 129
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 118
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 115
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 103
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 103
- 206010028980 Neoplasm Diseases 0.000 claims description 90
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 87
- 230000032258 transport Effects 0.000 claims description 74
- 230000003902 lesion Effects 0.000 claims description 70
- 238000000034 method Methods 0.000 claims description 68
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 62
- 208000002193 Pain Diseases 0.000 claims description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 60
- 208000014674 injury Diseases 0.000 claims description 59
- 230000036407 pain Effects 0.000 claims description 58
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims description 57
- 238000011282 treatment Methods 0.000 claims description 57
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 56
- 229960001193 diclofenac sodium Drugs 0.000 claims description 56
- 230000007170 pathology Effects 0.000 claims description 55
- 230000008733 trauma Effects 0.000 claims description 55
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 47
- 229960001259 diclofenac Drugs 0.000 claims description 47
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 44
- 150000003180 prostaglandins Chemical class 0.000 claims description 43
- 230000015572 biosynthetic process Effects 0.000 claims description 41
- 239000008223 sterile water Substances 0.000 claims description 41
- 238000003786 synthesis reaction Methods 0.000 claims description 38
- 241000701806 Human papillomavirus Species 0.000 claims description 35
- 210000004027 cell Anatomy 0.000 claims description 34
- 201000004681 Psoriasis Diseases 0.000 claims description 33
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 31
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 29
- 235000011187 glycerol Nutrition 0.000 claims description 29
- 229960001680 ibuprofen Drugs 0.000 claims description 29
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 26
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 26
- 239000002552 dosage form Substances 0.000 claims description 22
- 229960000905 indomethacin Drugs 0.000 claims description 22
- 229960003194 meglumine Drugs 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 21
- 208000009621 actinic keratosis Diseases 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 19
- 229960002702 piroxicam Drugs 0.000 claims description 19
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 19
- 239000003755 preservative agent Substances 0.000 claims description 19
- 230000002335 preservative effect Effects 0.000 claims description 19
- 229940124597 therapeutic agent Drugs 0.000 claims description 19
- 206010059313 Anogenital warts Diseases 0.000 claims description 18
- 238000009825 accumulation Methods 0.000 claims description 15
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 14
- 210000004324 lymphatic system Anatomy 0.000 claims description 14
- 229960002009 naproxen Drugs 0.000 claims description 14
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 14
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 13
- 239000002246 antineoplastic agent Substances 0.000 claims description 13
- 201000010881 cervical cancer Diseases 0.000 claims description 13
- 239000006071 cream Substances 0.000 claims description 13
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 13
- 229960004752 ketorolac Drugs 0.000 claims description 13
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 13
- 201000004384 Alopecia Diseases 0.000 claims description 12
- 208000003643 Callosities Diseases 0.000 claims description 12
- 208000000907 Condylomata Acuminata Diseases 0.000 claims description 12
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 12
- 206010064127 Solar lentigo Diseases 0.000 claims description 12
- 240000008042 Zea mays Species 0.000 claims description 12
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 12
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 12
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 claims description 12
- 201000004201 anogenital venereal wart Diseases 0.000 claims description 12
- 210000000481 breast Anatomy 0.000 claims description 12
- 235000005822 corn Nutrition 0.000 claims description 12
- 230000003676 hair loss Effects 0.000 claims description 12
- 208000024963 hair loss Diseases 0.000 claims description 12
- 230000036210 malignancy Effects 0.000 claims description 12
- 208000037819 metastatic cancer Diseases 0.000 claims description 12
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 12
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 12
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 11
- 208000021039 metastatic melanoma Diseases 0.000 claims description 11
- 210000003679 cervix uteri Anatomy 0.000 claims description 10
- 210000004904 fingernail bed Anatomy 0.000 claims description 10
- 230000002538 fungal effect Effects 0.000 claims description 10
- 230000000306 recurrent effect Effects 0.000 claims description 10
- 229960000588 flunixin Drugs 0.000 claims description 9
- NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 claims description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
- -1 acetylsalicylic acid, propionic acid derivatives Chemical class 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 239000008346 aqueous phase Substances 0.000 claims description 8
- MGCCHNLNRBULBU-WZTVWXICSA-N flunixin meglumine Chemical group CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O MGCCHNLNRBULBU-WZTVWXICSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 8
- 239000012071 phase Substances 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 8
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 claims description 6
- 229940041181 antineoplastic drug Drugs 0.000 claims description 6
- 230000000717 retained effect Effects 0.000 claims description 6
- CITBNDNUEPMTFC-UHFFFAOYSA-M sodium;2-(hydroxymethylamino)acetate Chemical compound [Na+].OCNCC([O-])=O CITBNDNUEPMTFC-UHFFFAOYSA-M 0.000 claims description 5
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960000469 flunixin meglumine Drugs 0.000 claims description 3
- 229940014041 hyaluronate Drugs 0.000 claims description 3
- 150000005599 propionic acid derivatives Chemical class 0.000 claims description 3
- 230000003381 solubilizing effect Effects 0.000 claims description 3
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- 239000008009 topical excipient Substances 0.000 claims 13
- XPJRQAIZZQMSCM-UHFFFAOYSA-N heptaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCO XPJRQAIZZQMSCM-UHFFFAOYSA-N 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 80
- 238000003756 stirring Methods 0.000 description 60
- 239000000499 gel Substances 0.000 description 45
- 230000000694 effects Effects 0.000 description 40
- 230000001684 chronic effect Effects 0.000 description 22
- 210000002540 macrophage Anatomy 0.000 description 19
- 230000004044 response Effects 0.000 description 19
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 15
- 229910001220 stainless steel Inorganic materials 0.000 description 14
- 239000010935 stainless steel Substances 0.000 description 14
- 238000001356 surgical procedure Methods 0.000 description 14
- 210000003127 knee Anatomy 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 159000000000 sodium salts Chemical class 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 206010034464 Periarthritis Diseases 0.000 description 10
- 230000000202 analgesic effect Effects 0.000 description 10
- 210000004207 dermis Anatomy 0.000 description 10
- 210000002683 foot Anatomy 0.000 description 10
- 210000005036 nerve Anatomy 0.000 description 10
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 8
- 210000003128 head Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 201000002481 Myositis Diseases 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000001613 neoplastic effect Effects 0.000 description 7
- IUQJDHJVPLLKFL-UHFFFAOYSA-N 2-(2,4-dichlorophenoxy)acetate;dimethylazanium Chemical compound CNC.OC(=O)COC1=CC=C(Cl)C=C1Cl IUQJDHJVPLLKFL-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 208000008035 Back Pain Diseases 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 5
- 208000000491 Tendinopathy Diseases 0.000 description 5
- 206010043255 Tendonitis Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 229940083741 banamine Drugs 0.000 description 5
- 230000036765 blood level Effects 0.000 description 5
- 239000003246 corticosteroid Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 210000002414 leg Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 201000004415 tendinitis Diseases 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 208000007882 Gastritis Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 208000035154 Hyperesthesia Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000008033 biological extinction Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 229960001334 corticosteroids Drugs 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000003637 steroidlike Effects 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 3
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 3
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 3
- 206010063045 Effusion Diseases 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010029240 Neuritis Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000000061 acid fraction Substances 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 210000003423 ankle Anatomy 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 210000000270 basal cell Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229960004544 cortisone Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 210000001061 forehead Anatomy 0.000 description 3
- 230000003779 hair growth Effects 0.000 description 3
- 210000004247 hand Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 201000009985 neuronitis Diseases 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000037311 normal skin Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000036269 ulceration Effects 0.000 description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- APQPGQGAWABJLN-UHFFFAOYSA-N Floctafenine Chemical compound OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=C(C(F)(F)F)C=CC=C12 APQPGQGAWABJLN-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 229960003240 floctafenine Drugs 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 229940089982 healon Drugs 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000008629 immune suppression Effects 0.000 description 2
- 230000037451 immune surveillance Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000005067 joint tissue Anatomy 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 230000008533 pain sensitivity Effects 0.000 description 2
- 208000003154 papilloma Diseases 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- CGMWMYHEKGCISN-UHFFFAOYSA-N (2-chloro-6-fluorophenyl)hydrazine Chemical compound NNC1=C(F)C=CC=C1Cl CGMWMYHEKGCISN-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000282709 Aotus trivirgatus Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000399988 Carinoma Species 0.000 description 1
- 241000561734 Celosia cristata Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
- 229940019097 EMLA Drugs 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 206010023509 Kyphosis Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101100384355 Mus musculus Ctnnbip1 gene Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010029469 Nodal osteoarthritis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- KSQXVLVXUFHGJQ-UHFFFAOYSA-M Sodium ortho-phenylphenate Chemical compound [Na+].[O-]C1=CC=CC=C1C1=CC=CC=C1 KSQXVLVXUFHGJQ-UHFFFAOYSA-M 0.000 description 1
- 206010041738 Sports injury Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000002240 Tennis Elbow Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003377 anti-microbal effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000002965 anti-thrombogenic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 208000015100 cartilage disease Diseases 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 201000005043 chondromalacia Diseases 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000005574 cross-species transmission Effects 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229940075911 depen Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- UZUODNWWWUQRIR-UHFFFAOYSA-L disodium;3-aminonaphthalene-1,5-disulfonate Chemical compound [Na+].[Na+].C1=CC=C(S([O-])(=O)=O)C2=CC(N)=CC(S([O-])(=O)=O)=C21 UZUODNWWWUQRIR-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000002320 enamel (paints) Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000000256 facial nerve Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000001872 metatarsal bone Anatomy 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 210000005164 penile vein Anatomy 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 229940049529 sodium hyaluronate 20 mg/ml Drugs 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 239000008328 tiger balm Substances 0.000 description 1
- 229940096662 tiger balm Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940126702 topical medication Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940063674 voltaren Drugs 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002061703A CA2061703C (en) | 1992-02-20 | 1992-02-20 | Formulations containing hyaluronic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9300491A0 AP9300491A0 (en) | 1993-04-30 |
| AP475A true AP475A (en) | 1996-03-08 |
Family
ID=4149316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1993/000491A AP475A (en) | 1992-02-20 | 1993-02-19 | Pharmaceutical formulations containing hyaluronic acid. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6140312A (de) |
| EP (1) | EP0626863B1 (de) |
| JP (1) | JPH07506812A (de) |
| KR (1) | KR100315371B1 (de) |
| CN (1) | CN1103219C (de) |
| AP (1) | AP475A (de) |
| AT (1) | ATE200736T1 (de) |
| AU (1) | AU3488893A (de) |
| CA (1) | CA2061703C (de) |
| CZ (1) | CZ290637B6 (de) |
| DE (1) | DE69330180T2 (de) |
| DK (1) | DK0626863T3 (de) |
| ES (1) | ES2156124T3 (de) |
| FI (1) | FI113522B (de) |
| GR (1) | GR3036164T3 (de) |
| HK (1) | HK1005983A1 (de) |
| HU (2) | HU225967B1 (de) |
| IN (5) | IN175918B (de) |
| MD (1) | MD960307A (de) |
| MX (1) | MX9300904A (de) |
| NO (1) | NO312939B1 (de) |
| NZ (2) | NZ249071A (de) |
| PL (1) | PL173211B1 (de) |
| PT (1) | PT626863E (de) |
| RO (1) | RO117499B1 (de) |
| SG (1) | SG52416A1 (de) |
| SK (1) | SK11193A3 (de) |
| WO (1) | WO1993016732A1 (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2122519C (en) * | 1994-04-29 | 2001-02-20 | Rudolf Edgar Dr. Falk | Cancer treatment and metastasis prevention |
| CA2130762C (en) * | 1994-08-24 | 1999-07-06 | Eva Anne Turley | Treatment of disease and conditions associated with macrophage infiltration |
| WO1996004922A1 (en) * | 1994-08-10 | 1996-02-22 | Davis, Joanne, T. | Method of using hyaluronic acid for the detection, location and diagnosis of tumors |
| AU3159595A (en) * | 1994-08-30 | 1996-03-22 | Hyal Pharmaceutical Corporation | Hyaluronic acid and derivatives for modulation of cellular activity |
| JP4010574B2 (ja) * | 1994-12-05 | 2007-11-21 | 電気化学工業株式会社 | 皮膚外用剤 |
| US5626838A (en) * | 1995-03-13 | 1997-05-06 | The Procter & Gamble Company | Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx |
| CA2154103C (en) * | 1995-07-18 | 1998-02-24 | Samuel Simon Asculai | Treatment of mucous membrane disease, trauma or condition and for the relief of pain |
| US6875753B1 (en) | 1996-03-14 | 2005-04-05 | The Governors Of The University Of Alberta | Methods for cell mobilization using in vivo treatment with hyaluronan (HA) |
| US5939047A (en) * | 1996-04-16 | 1999-08-17 | Jernberg; Gary R. | Local delivery of chemotherapeutic agents for treatment of periodontal disease |
| EP0963196B1 (de) | 1996-09-27 | 2005-01-19 | Jagotec Ag | Arzneistoffverabreichungssystem mit hyaluronsäure |
| ATE284954T1 (de) * | 1997-10-31 | 2005-01-15 | Univ Oklahoma | Hyaluronan synthase gen und seine verwendung |
| IL138803A0 (en) * | 1998-04-02 | 2001-10-31 | Univ Oklahoma | Nucleic acid encoding hyaluronan synthase |
| DE59906391D1 (de) * | 1998-12-23 | 2003-08-28 | Esparma Gmbh | Mittel zum schutz der haut enthaltend hydrolysierte hyaluronsäure |
| EP1140198B1 (de) | 1999-01-13 | 2007-10-31 | Alchemia Oncology Pty Limited | Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln |
| US9066919B2 (en) | 2000-07-14 | 2015-06-30 | Alchemia Oncology Pty Limited | Hyaluronan as a chemo-sensitizer in the treatment of cancer |
| AUPQ879500A0 (en) | 2000-07-14 | 2000-08-10 | Meditech Research Limited | Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease |
| US6828308B2 (en) * | 2000-07-28 | 2004-12-07 | Sinclair Pharmaceuticals, Ltd. | Compositions and methods for the treatment or prevention of inflammation |
| US6576226B1 (en) | 2000-11-17 | 2003-06-10 | Gary R. Jernberg | Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease |
| US6726898B2 (en) | 2000-11-17 | 2004-04-27 | Gary R. Jernberg | Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease |
| CA2456966A1 (en) * | 2001-08-14 | 2003-02-27 | Tel Aviv University Future Technology Development Lp | Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| US20030143165A1 (en) * | 2002-01-25 | 2003-07-31 | Allan Evans | NSAID-containing topical formulations that demonstrate chemopreventive activity |
| US7622117B2 (en) | 2002-04-17 | 2009-11-24 | Dynamis Therapeutics, Inc. | 3-deoxyglucosone and skin |
| US20050142208A1 (en) | 2002-05-09 | 2005-06-30 | Won Min Yoo | Pharmceutical composition for treatment of wounds conntaining blood plasma or serum |
| AU2003291872A1 (en) * | 2002-12-04 | 2004-06-23 | Inrs (Institut National De Recherche Scientifique) | An exopolysaccharides delivery system for active molecules |
| AU2005203988B2 (en) * | 2004-01-07 | 2010-11-11 | Seikagaku Corporation | Hyaluronic acid derivative and drug containing the same |
| FR2865651B1 (fr) * | 2004-01-29 | 2007-09-28 | Fabre Pierre Dermo Cosmetique | Compositions topiques associant des fragments de hyaluronate de sodium et un retinoide utiles en dermatologie cosmetique et medicale |
| US20050266064A1 (en) * | 2004-05-29 | 2005-12-01 | Mccarthy Kathryn J | Cosmetic compositions and methods |
| CA2616607C (en) | 2005-07-27 | 2015-06-02 | Alchemia Oncology Pty Limited | Therapeutic protocols using hyaluronan |
| US7323184B2 (en) | 2005-08-22 | 2008-01-29 | Healagenics, Inc. | Compositions and methods for the treatment of wounds and the reduction of scar formation |
| US8623354B2 (en) | 2005-09-07 | 2014-01-07 | Alchemia Oncology Pty Limited | Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
| EP1998788A4 (de) * | 2006-03-01 | 2011-08-03 | Ruey J Yu | Zusammensetzung und verfahren zur topischen behandlung teer-responsiver hauterkrankungen |
| ES2621876T3 (es) | 2006-09-13 | 2017-07-05 | Enhance Skin Products Inc. | Composición cosmética para el tratamiento de la piel y procedimientos de la misma |
| WO2008073295A2 (en) * | 2006-12-07 | 2008-06-19 | Surmodics, Inc. | Latent stabilization of bioactive agents releasable from implantable medical articles |
| ITMI20071267A1 (it) * | 2007-06-22 | 2008-12-23 | Fidia Farmaceutici | Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative |
| GB0913442D0 (en) | 2009-07-31 | 2009-09-16 | Univ Ramot | Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof |
| ITMI20110644A1 (it) * | 2011-04-14 | 2012-10-15 | Giuliani Spa | Sistema per il rilascio prolungato di agenti cosmetici |
| WO2013156989A1 (en) | 2012-04-18 | 2013-10-24 | Ramot At Tel-Aviv University Ltd. | Lipidated glycosaminoglycan particles for the delivery of nucleic acids |
| FR2994846B1 (fr) | 2012-08-29 | 2014-12-26 | Vivacy Lab | Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium |
| KR101439032B1 (ko) * | 2013-06-13 | 2014-09-05 | 동아에스티 주식회사 | 피록시캄과 히알루론산을 포함하는 골관절염 치료를 위한 액상 조성물 |
| EP3160448A4 (de) | 2014-06-26 | 2018-11-14 | Ramot at Tel-Aviv University Ltd. | Liposomale formulierungen zur freisetzung von nukleinsäuren |
| SG11201703192SA (en) | 2014-11-21 | 2017-05-30 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| KR102591220B1 (ko) * | 2015-09-04 | 2023-10-18 | 폴리 엠디 에스.알.엘. | 인유두종 바이러스 피부 감염의 치료를 위한 아세틸살리실산을 포함하는 조성물 및 의료 장치 |
| CN109965104A (zh) * | 2019-03-29 | 2019-07-05 | 华熙生物科技股份有限公司 | 一种含透明质酸钠的组合物及其制备方法和应用 |
| WO2021173749A1 (en) * | 2020-02-25 | 2021-09-02 | Amplifica, Inc. | Compositions and methods for stimulating hair growth |
| KR102368100B1 (ko) | 2020-07-20 | 2022-02-25 | 영인기술(주) | 변압기용 단자 조립 어셈블리 |
| CN112587475B (zh) * | 2020-12-18 | 2022-09-13 | 华熙生物科技股份有限公司 | 一种载药凝胶及其制备方法 |
| KR20240133242A (ko) | 2023-02-28 | 2024-09-04 | 영인에너지솔루션 주식회사 | 변압기의 혼촉 및 방전 방지용 단자 어셈블리 |
| CN117304368B (zh) * | 2023-11-29 | 2024-03-01 | 杭州湃肽生化科技有限公司 | 一种透明质酸钠与胶原五肽的组合物及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0197718A2 (de) * | 1985-04-05 | 1986-10-15 | FIDIA S.p.A. | Arzneimittel zur topischen Anwendung |
| EP0368253A2 (de) * | 1988-11-08 | 1990-05-16 | UNION CARBIDE CHEMICALS AND PLASTICS COMPANY INC. (a New York corporation) | Abgabesystem für pharmazeutische oder therapeutische Wirkstoffe |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2583096A (en) * | 1949-01-15 | 1952-01-22 | Searle & Co | Process for the production of high viscosity hyaluronic acid |
| GB769287A (en) | 1954-08-18 | 1957-03-06 | American Home Prod | Preparation of partially depolymerized hyaluronic acid and therapeutic compositions thereof |
| GB818336A (en) | 1956-06-22 | 1959-08-12 | Erba Carlo Spa | A new acid aminopolysaccharide and a process for the production thereof |
| US3042667A (en) * | 1959-03-10 | 1962-07-03 | Pharmacia Ab | Process for producing dextran derivatives and products resulting therefrom |
| FR1425265A (fr) * | 1962-05-14 | 1966-01-24 | Parke Davis & Co | Procédé de préparation d'un nouveau polysaccharide et de ses sels |
| NL123338C (de) * | 1961-12-08 | |||
| FR3715M (fr) * | 1964-06-11 | 1965-11-29 | Lucien Nouvel | Antithermiques et antirhumatismaux améliorés. |
| US3357784A (en) * | 1964-09-30 | 1967-12-12 | Kendall & Co | Exposure to intense ultraviolet light to improve characteristics of cellulosic fabrics in divinyl sulfone and glyoxal cross-linking processes |
| AT252264B (de) * | 1965-03-17 | 1967-02-10 | Etapharm Chem Pharm Lab Ges M | Verfahren zur Herstellung eines reinen hochviskosen Hyaluronsäurepräparates |
| US3887703A (en) * | 1967-03-24 | 1975-06-03 | Oreal | Mucopolysaccharides, their preparation and use in cosmetic and pharmaceutical compositions |
| US3792164A (en) * | 1970-03-31 | 1974-02-12 | Chemway Corp | Ophthalmic composition comprising water-soluble alkaloid salts of polyuronic acids |
| GB1283892A (en) | 1970-06-08 | 1972-08-02 | Irwin Irville Lubowe | Improvements in and relating to medicinal compositions for application to the skin and/or hair |
| US3870791A (en) * | 1972-04-24 | 1975-03-11 | Heskel M Haddad | Solid state ophthalmic medication delivery method |
| US3845201A (en) * | 1972-04-24 | 1974-10-29 | S Loucas | Solid state ophthalmic medication delivery method |
| DE2364373A1 (de) * | 1973-12-22 | 1975-07-10 | Hahn Carl Dr Gmbh | Pharmazeutische und kosmetische praeparate zur aeusserlichen anwendung |
| US4003991A (en) * | 1974-08-27 | 1977-01-18 | National Patent Development Corporation | Ophthalmic formulation |
| US4280954A (en) * | 1975-07-15 | 1981-07-28 | Massachusetts Institute Of Technology | Crosslinked collagen-mucopolysaccharide composite materials |
| GB1515963A (en) * | 1975-07-15 | 1978-06-28 | Massachusetts Inst Technology | Crosslinked collagen-mucopolysaccharide composite materials |
| US4045558A (en) * | 1975-10-08 | 1977-08-30 | Merck & Co., Inc. | Pilocarpine salts |
| US4141973A (en) * | 1975-10-17 | 1979-02-27 | Biotrics, Inc. | Ultrapure hyaluronic acid and the use thereof |
| US4061722A (en) * | 1976-04-26 | 1977-12-06 | Interx Research Corporation | Selected quaternary ammonium salts of pilocarpine useful in reducing intraocular pressure in warm-blooded animals |
| US4470975A (en) * | 1977-10-21 | 1984-09-11 | The Johns Hopkins University | Method and composition for the elimination of water from an animal body |
| US4271143A (en) * | 1978-01-25 | 1981-06-02 | Alcon Laboratories, Inc. | Sustained release ophthalmic drug dosage |
| FR2478646A2 (fr) * | 1980-03-20 | 1981-09-25 | Choay Sa | Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir |
| US4255415A (en) * | 1978-11-22 | 1981-03-10 | Schering Corporation | Polyvinyl alcohol ophthalmic gel |
| US4240163A (en) * | 1979-01-31 | 1980-12-23 | Galin Miles A | Medicament coated intraocular lens |
| US4272522A (en) * | 1979-10-15 | 1981-06-09 | Balazs Endre A | Method for stimulating phagocytic activity and synergistic compositions therefor |
| US4303676A (en) | 1980-03-21 | 1981-12-01 | Balazs Endre A | Hyaluronate based compositions and cosmetic formulations containing same |
| US4328803B1 (en) * | 1980-10-20 | 1994-01-11 | Opthalmic Systems, Inc. | Opthalmological procedures |
| JPS57185208A (en) * | 1981-05-07 | 1982-11-15 | Shiseido Co Ltd | Skin cosmetic |
| DE3273138D1 (en) * | 1981-06-02 | 1986-10-16 | Eupan Corp | Eustatic composition for nonspecifically facilitating and amplifying the generalized homeostatic regulation and maintenance, compensation and repair in living organisms |
| US4684627A (en) * | 1981-09-08 | 1987-08-04 | Leveen Harry H | Treatment of cancer with phlorizin and its derivatives |
| JPS58183611A (ja) * | 1982-04-19 | 1983-10-26 | Kanebo Ltd | 多相乳化型化粧料 |
| JPS58183938A (ja) * | 1982-04-21 | 1983-10-27 | Shiseido Co Ltd | 乳化組成物 |
| JPS5925311A (ja) * | 1982-07-29 | 1984-02-09 | Shiseido Co Ltd | 化粧料 |
| US5166331A (en) * | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
| US4517295A (en) * | 1983-02-18 | 1985-05-14 | Diagnostic, Inc. | Hyaluronic acid from bacterial culture |
| US4478822A (en) * | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| JPS59219209A (ja) * | 1983-05-28 | 1984-12-10 | Kanebo Ltd | 皮膚化粧料 |
| AU555747B2 (en) * | 1983-08-09 | 1986-10-09 | Cilco Inc. | Chondroitin sulfate and sodium hyaluronate composition |
| DE3482812D1 (de) * | 1983-10-11 | 1990-08-30 | Fidia Spa | Fraktionen von hyaluronsaeure mit pharmazeutischer aktivitaet, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen. |
| US4855134A (en) * | 1983-10-14 | 1989-08-08 | Sumitomo Pharmaceuticals Company, Limited | Sustained-release preparation |
| DE3486029T2 (de) * | 1983-10-14 | 1993-05-13 | Sumitomo Pharma | Ifn-praeparat mit verzoegerter abgabe fuer parentale verabreichung. |
| NO161573C (no) * | 1983-11-25 | 1989-08-30 | Miles Inc | Fremgangsmaate til fremstilling av hyaluronsyre. |
| US4500676A (en) * | 1983-12-15 | 1985-02-19 | Biomatrix, Inc. | Hyaluronate modified polymeric articles |
| US4487865A (en) * | 1983-12-15 | 1984-12-11 | Biomatrix, Inc. | Polymeric articles modified with hyaluronate |
| US4716224A (en) * | 1984-05-04 | 1987-12-29 | Seikagaku Kogyo Co. Ltd. | Crosslinked hyaluronic acid and its use |
| US4711780A (en) * | 1984-06-11 | 1987-12-08 | Fahim Mostafa S | Composition and process for promoting epithelial regeneration |
| US4629623A (en) * | 1984-06-11 | 1986-12-16 | Biomatrix, Inc. | Hyaluronate-poly (ethylene oxide) compositions and cosmetic formulations thereof |
| US4863907A (en) * | 1984-06-29 | 1989-09-05 | Seikagaku Kogyo Co., Ltd. | Crosslinked glycosaminoglycans and their use |
| JPS6156114A (ja) * | 1984-08-27 | 1986-03-20 | Kanebo Ltd | 皮膚老化防止用化粧料 |
| JPS6164701A (ja) * | 1984-09-06 | 1986-04-03 | Meito Sangyo Kk | カチオン化デキストラン誘導体とポリウロン酸の高分子電解質錯体及びその利用 |
| JPS61106602A (ja) * | 1984-10-31 | 1986-05-24 | Meito Sangyo Kk | カチオン性デキストラン誘導体の高分子電解質錯体及びその利用 |
| US4582865A (en) * | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
| US4636524A (en) * | 1984-12-06 | 1987-01-13 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
| US4784990A (en) * | 1985-01-18 | 1988-11-15 | Bio-Technology General Corporation | High molecular weight sodium hyaluronate |
| US4713448A (en) * | 1985-03-12 | 1987-12-15 | Biomatrix, Inc. | Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues |
| SE8501723L (sv) * | 1985-04-09 | 1986-10-10 | Pharmacia Ab | Preparation att anvendas vid behandling av ledinflammation |
| US4725585A (en) * | 1985-04-26 | 1988-02-16 | Pharmacia Ab | Method of enhancing the host defense |
| EP0207638B1 (de) * | 1985-06-04 | 1990-12-19 | Teijin Limited | Arzneizubereitung mit verzögerter Wirkstoffabgabe |
| US4851521A (en) * | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
| US4820732A (en) * | 1985-10-04 | 1989-04-11 | The Upjohn Company | Method and compositions for reducing dysfunction in angioplasty procedures |
| SE449003B (sv) * | 1985-10-18 | 1987-03-30 | Pharmacia Ab | Sett att in vitro avskilja spermier med egen rorelseformaga medelst penetrationsmedium i vilket ingar hyaluronsyrasalt |
| IN166447B (de) * | 1985-11-27 | 1990-05-12 | Ethicon Inc | |
| EP0224987B1 (de) * | 1985-11-29 | 1992-04-15 | Biomatrix, Inc. | Arzneistoffabgabesysteme auf Basis von Hyaluronan, dessen Derivaten und Salzen sowie Verfahren zu deren Herstellung |
| US4912093A (en) * | 1986-10-01 | 1990-03-27 | Marion Laboratories, Inc. | Use of synthetic sulfated saccharides to enhance wound healing |
| US4746504A (en) * | 1986-03-14 | 1988-05-24 | Bio-Technology General Corp. | Heavy metal salts of hyaluronic acid and their use as antimicrobial agents |
| US4784991A (en) * | 1986-03-14 | 1988-11-15 | Bio-Technology General Corp. | Heavy metal salts of hyaluronic acid and their use as antimicrobial agents |
| DE3610037A1 (de) * | 1986-03-21 | 1987-09-24 | Schering Ag | Nifedipinkombinationspraeparat |
| EP0240098A3 (de) * | 1986-04-04 | 1989-05-10 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Oligo und Polysaccharide zur Behandlung von Krankheiten verursacht durch Retroviren |
| US4808576A (en) * | 1986-04-28 | 1989-02-28 | Mobay Corporation | Remote administration of hyaluronic acid to mammals |
| EP0244178A3 (de) * | 1986-04-28 | 1989-02-08 | Iolab, Inc | Intraokuläre Mittel und Verfahren zu deren Verwendung |
| SE452469B (sv) * | 1986-06-18 | 1987-11-30 | Pharmacia Ab | Material bestaende av en tverbunden karboxylgrupphaltig polysackarid och forfarande vid framstellning av detsamma |
| US4877619A (en) * | 1986-08-25 | 1989-10-31 | Vestar, Inc. | Liposomal vesicles for intraperitoneal administration of therapeutic agents |
| JPH0725689B2 (ja) * | 1986-10-07 | 1995-03-22 | 中外製薬株式会社 | 顆粒球コロニ−刺激因子を含有する徐放性製剤 |
| IT1198449B (it) * | 1986-10-13 | 1988-12-21 | F I D I Farmaceutici Italiani | Esteri di alcoli polivalenti di acido ialuronico |
| US4879282A (en) * | 1987-03-17 | 1989-11-07 | Saliba Jr Michael J | Medical application for heparin and related molecules |
| US5145841A (en) * | 1987-03-19 | 1992-09-08 | Arthropharm Pty. Limited | Anti-inflammatory compounds and compositions |
| US4795741A (en) * | 1987-05-06 | 1989-01-03 | Biomatrix, Inc. | Compositions for therapeutic percutaneous embolization and the use thereof |
| GB8713662D0 (en) * | 1987-06-11 | 1987-07-15 | Skandigen Ab | Hyaluronic acid derivatives |
| US4944941A (en) * | 1987-08-07 | 1990-07-31 | Genentech, Inc. | Methods and compositions for the treatment of lung conditions |
| US4900550A (en) * | 1987-08-19 | 1990-02-13 | Amy Allene Cosmetiques, Inc. | Skin care cosmetic regime |
| US4937270A (en) * | 1987-09-18 | 1990-06-26 | Genzyme Corporation | Water insoluble derivatives of hyaluronic acid |
| US4913898A (en) * | 1988-04-06 | 1990-04-03 | Altobella Hair Products Inc. | Hair treatment composition and method |
| IT1219587B (it) * | 1988-05-13 | 1990-05-18 | Fidia Farmaceutici | Polisaccaridi carbossiilici autoreticolati |
| CA2004740A1 (en) * | 1988-12-07 | 1990-06-07 | Cary Linsky | Low molecular weight heparin, heparinoid and hexuronyl hexosaminoglycan sulfate containing adhesion prevention barrier and process |
| AU628910B2 (en) * | 1988-12-20 | 1992-09-24 | La Jolla Cancer Research Foundation | Polypeptide-polymer conjugates active in wound healing |
| DE3900198A1 (de) * | 1989-01-05 | 1990-07-12 | Merck Patent Gmbh | Topisch anwendbare pharmazeutische zubereitung |
| JPH0341033A (ja) * | 1989-07-07 | 1991-02-21 | Kyowa Hakko Kogyo Co Ltd | 安定なモチリン類含有製剤 |
| CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
| US5095037B1 (en) * | 1989-12-21 | 1995-12-19 | Nissho Kk | Combined anti-inflammatory agent |
| US5092841A (en) * | 1990-05-17 | 1992-03-03 | Wayne State University | Method for treating an arterial wall injured during angioplasty |
| US5116864A (en) * | 1991-04-09 | 1992-05-26 | Indiana University Foundation | Method for preventing restenosis following reconfiguration of body vessels |
| US5116331A (en) * | 1991-04-23 | 1992-05-26 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Pressure transducer and system for cryogenic environments |
-
1992
- 1992-02-20 CA CA002061703A patent/CA2061703C/en not_active Expired - Lifetime
-
1993
- 1993-02-16 AT AT93903754T patent/ATE200736T1/de active
- 1993-02-16 DK DK93903754T patent/DK0626863T3/da active
- 1993-02-16 RO RO94-01388A patent/RO117499B1/ro unknown
- 1993-02-16 HU HU9303282A patent/HU225967B1/hu unknown
- 1993-02-16 SG SG1996004145A patent/SG52416A1/en unknown
- 1993-02-16 IN IN94CA1993 patent/IN175918B/en unknown
- 1993-02-16 EP EP93903754A patent/EP0626863B1/de not_active Expired - Lifetime
- 1993-02-16 AU AU34888/93A patent/AU3488893A/en not_active Abandoned
- 1993-02-16 JP JP5514407A patent/JPH07506812A/ja active Pending
- 1993-02-16 DE DE69330180T patent/DE69330180T2/de not_active Expired - Lifetime
- 1993-02-16 NZ NZ249071A patent/NZ249071A/en not_active IP Right Cessation
- 1993-02-16 PL PL93301149A patent/PL173211B1/pl unknown
- 1993-02-16 ES ES93903754T patent/ES2156124T3/es not_active Expired - Lifetime
- 1993-02-16 WO PCT/CA1993/000061 patent/WO1993016732A1/en active IP Right Grant
- 1993-02-16 PT PT93903754T patent/PT626863E/pt unknown
- 1993-02-16 MD MD96-0307A patent/MD960307A/ro not_active Application Discontinuation
- 1993-02-16 NZ NZ299280A patent/NZ299280A/en not_active IP Right Cessation
- 1993-02-18 CZ CZ1993230A patent/CZ290637B6/cs not_active IP Right Cessation
- 1993-02-19 AP APAP/P/1993/000491A patent/AP475A/en active
- 1993-02-19 MX MX9300904A patent/MX9300904A/es unknown
- 1993-02-20 CN CN93103488A patent/CN1103219C/zh not_active Expired - Lifetime
- 1993-05-05 SK SK11193A patent/SK11193A3/sk unknown
-
1994
- 1994-08-17 NO NO19943044A patent/NO312939B1/no not_active IP Right Cessation
- 1994-08-17 FI FI943789A patent/FI113522B/fi not_active IP Right Cessation
- 1994-08-19 KR KR1019940702859A patent/KR100315371B1/ko not_active IP Right Cessation
-
1995
- 1995-03-13 IN IN272CA1995 patent/IN179130B/en unknown
- 1995-03-13 IN IN270CA1995 patent/IN182267B/en unknown
- 1995-03-13 IN IN271CA1995 patent/IN182348B/en unknown
- 1995-03-14 IN IN293CA1995 patent/IN178280B/en unknown
- 1995-06-06 US US08/466,714 patent/US6140312A/en not_active Expired - Lifetime
- 1995-06-30 HU HU95P/P00652P patent/HU211823A9/hu unknown
-
1998
- 1998-06-10 HK HK98105085A patent/HK1005983A1/xx not_active IP Right Cessation
-
2001
- 2001-07-02 GR GR20010401015T patent/GR3036164T3/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0197718A2 (de) * | 1985-04-05 | 1986-10-15 | FIDIA S.p.A. | Arzneimittel zur topischen Anwendung |
| EP0368253A2 (de) * | 1988-11-08 | 1990-05-16 | UNION CARBIDE CHEMICALS AND PLASTICS COMPANY INC. (a New York corporation) | Abgabesystem für pharmazeutische oder therapeutische Wirkstoffe |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP475A (en) | Pharmaceutical formulations containing hyaluronic acid. | |
| US5824658A (en) | Topical composition containing hyaluronic acid and NSAIDS | |
| US5977088A (en) | Formulations containing hyaluronic acid | |
| AU768058B2 (en) | Topical composition containing hyaluronic acid and NSAIDs | |
| US5914322A (en) | Treatment of disease and conditions | |
| US6147059A (en) | Formulations containing hyaluronic acid | |
| US5910489A (en) | Topical composition containing hyaluronic acid and NSAIDS | |
| US5792753A (en) | Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs | |
| US6218373B1 (en) | Formulations containing hyaluronic acid | |
| US6114314A (en) | Formulations containing hyaluronic acid | |
| US6017900A (en) | Topical composition containing hyaluronic acid and nsaids | |
| US6103704A (en) | Therapeutic methods using hyaluronic acid | |
| US5990096A (en) | Formulations containing hyaluronic acid | |
| US6087344A (en) | Formulations containing hyaluronic acid | |
| CA2089621A1 (en) | Formulations containing hyaluronic acid | |
| CA2089635A1 (en) | Treatment of disease employing hyaluronic acid and nsaids |